01
Location:
Homepage
/
/
Nimotuzumab(Trade name:Tai Xinsheng®)

Nimotuzumab(Trade name:Tai Xinsheng®)

Nimotuzumab(Trade name:Tai Xinsheng®)

In the 1970s, scientists found out that monoclonal antibodies can specifically target tumor cells, which triggered significant changes in cancer treatment since then. BPL has focused on the clinical application of monoclonal antibodies to treat patients with cancer since 1999, and developed China’s first humanized monoclonal antibody Nimotuzumab (Tai Xin Sheng), which was approved to treat patients with nasopharyngeal cancer in China and put into market in 2008. Nimotuzumab targets epidermal growth factor receptor (EGFR), and is believed to be candidate for the treatment of multiple solid tumors, concerning EGFR participates in the occurrence and development of various malignant tumors by leading to cell proliferation and apoptosis.    Nimotuzumab (trade name in China Tai Xin Sheng®, Registration ID: 2005S02236) was approved in China in 2008 as a drug in combination with RT for a treatment of NPC and was included within Chinese NCCN guideline as a recommended targeted therapy for this indication in 2009.   Post marketing experience in NPC reinforces the safety within Chinese population. More than 30,000 patients received this therapy with an excellent safety profile in China and throughout the world. Five phase III clinical trials are ongoing in different tumors from epithelial origin with different schedules of treatment, with the approval of the China Food and Drug Administration (CFDA). For this reason, physicians have used nimotuzumab as an “off-label product” in other cancers of epithelial origin.   After seven years of the first approval in China, the information of several advanced cancer patients who received nimotuzumab in combination with CT in off-label approach has been collected. This retrospective analysis summarizes the safety profile, efficacy and possible predictive factors of this anti-EGFR therapy in Chinese patients with advanced cancers.
服务热线 400-659-2330
Taixinsheng

——Anti-EGFR humanized monoclonal antibody

In the 1970s, scientists found out that monoclonal antibodies can specifically target tumor cells, which triggered significant changes in cancer treatment since then. BPL has focused on the clinical application of monoclonal antibodies to treat patients with cancer since 1999, and developed China’s first humanized monoclonal antibody Nimotuzumab (Tai Xin Sheng), which was approved to treat patients with nasopharyngeal cancer in China and put into market in 2008. Nimotuzumab targets epidermal growth factor receptor (EGFR), and is believed to be candidate for the treatment of multiple solid tumors, concerning EGFR participates in the occurrence and development of various malignant tumors by leading to cell proliferation and apoptosis.  
According to various clinical trials of Nimotuzumab, it demonstrates great efficacy in treating patients with head and neck cancer, pancreatic cancer, breast cancer, gliomas, NSCLC and so on, and significantly improve the quality of life of patients and extent their life cycle. Now clinical trials of Nimotuzumab along with/without chemotherapy and radiotherapy to treat patients with H&N cancer, esophageal cancer, pancreatic cancer, high-grade pediatric gliomas are under going.
What distinguishes Nimotuzumab from other antibodies is its outstanding safety profile, which has been confirmed by tens of thousands of patients at home and abroad. It is widely agreed that Nimotuzumab can protect normal cells while killing tumor cells, which results in the strong specificity and high bioavailability. Therefore, Nimotuzumab has been successfully recorded into the national medical insurance catalogue in 2017, 2019 and 2021, which enables more cancer patients can benefit from its use. 

Previous
Next
搜索

Biotech pharmaceutical co., Ltd

Address:NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176

Biotech pharmaceutical co., Ltd  京ICP备05019954号 互联网药品信息编号:(京)非经营性2016-0046    www.300.cn